ATE443527T1 - 5-cnac zur oralen verabreichung von parathormonfragmenten - Google Patents

5-cnac zur oralen verabreichung von parathormonfragmenten

Info

Publication number
ATE443527T1
ATE443527T1 AT02794796T AT02794796T ATE443527T1 AT E443527 T1 ATE443527 T1 AT E443527T1 AT 02794796 T AT02794796 T AT 02794796T AT 02794796 T AT02794796 T AT 02794796T AT E443527 T1 ATE443527 T1 AT E443527T1
Authority
AT
Austria
Prior art keywords
parathormone
cnac
fragments
oral administration
methods
Prior art date
Application number
AT02794796T
Other languages
English (en)
Inventor
Moise Azria
Simon Bateman
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE443527T1 publication Critical patent/ATE443527T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02794796T 2001-08-17 2002-08-16 5-cnac zur oralen verabreichung von parathormonfragmenten ATE443527T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31304801P 2001-08-17 2001-08-17
PCT/EP2002/009181 WO2003015822A1 (en) 2001-08-17 2002-08-16 5-cnac as oral delivery agent for parathyroid hormone fragments

Publications (1)

Publication Number Publication Date
ATE443527T1 true ATE443527T1 (de) 2009-10-15

Family

ID=23214149

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02794796T ATE443527T1 (de) 2001-08-17 2002-08-16 5-cnac zur oralen verabreichung von parathormonfragmenten

Country Status (26)

Country Link
US (4) US20040242478A1 (de)
EP (1) EP1420827B8 (de)
JP (2) JP4959917B2 (de)
KR (1) KR20040030120A (de)
CN (1) CN1279981C (de)
AT (1) ATE443527T1 (de)
AU (1) AU2002333443C1 (de)
BR (1) BRPI0211932B1 (de)
CA (1) CA2453646C (de)
CO (1) CO5560586A2 (de)
CY (1) CY1109661T1 (de)
DE (1) DE60233803D1 (de)
DK (1) DK1420827T3 (de)
EC (1) ECSP044961A (de)
ES (1) ES2333587T3 (de)
HU (1) HUP0401441A3 (de)
IL (2) IL159714A0 (de)
MX (1) MXPA04001418A (de)
NO (1) NO328069B1 (de)
NZ (1) NZ531018A (de)
PL (1) PL210258B1 (de)
PT (1) PT1420827E (de)
RU (1) RU2322256C2 (de)
SI (1) SI1420827T1 (de)
WO (1) WO2003015822A1 (de)
ZA (1) ZA200400242B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5073153B2 (ja) * 2001-06-01 2012-11-14 ノバルティス アーゲー 副甲状腺ホルモンおよびカルシトニンの経口投与
KR20040030120A (ko) * 2001-08-17 2004-04-08 노파르티스 아게 부갑상선 호르몬 단편의 경구 전달제로서의 5-ｃｎａｃ
EP1496911B1 (de) * 2002-04-10 2007-12-19 University Of Virginia Patent Foundation Verwendung von a2a adenosin rezeptor agonisten und anti-pathogene mittel enthaltenden kombinationen zur behandlung von entzündungskrankheiten
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
ES2398237T3 (es) 2003-07-23 2013-03-14 Novartis Ag Uso de calcitonina en osteoartritis
GB0427600D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
US8110547B2 (en) * 2005-01-12 2012-02-07 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
JP2008543855A (ja) * 2005-06-13 2008-12-04 ライジェル ファーマシューティカルズ， インコーポレイテッド 変形性骨疾患を処置するための方法および組成物
CN105641686A (zh) 2005-09-19 2016-06-08 爱密斯菲尔科技公司 N-(5-氯水杨酰基)-8-氨基辛酸的二钠盐的晶形
GB0522566D0 (en) 2005-11-04 2005-12-14 Novartis Ag Organic compounds
CA2628945A1 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
BRPI0716261A2 (pt) * 2006-08-31 2013-08-06 Novartis Ag composiÇÕes farmacÊuticas compreendendo hch para distribuiÇço oral
CN101621991A (zh) 2007-03-02 2010-01-06 诺瓦提斯公司 降钙素的口服施用
PL2215047T3 (pl) 2007-11-02 2014-05-30 Emisphere Tech Inc Sposób leczenia niedoborów witaminy b12
BR112012013725A2 (pt) 2009-12-07 2017-01-10 Univ Michigan Tech paratormônio de urso preto e métodos de usar o paratormônio de uso preto.
WO2012130193A1 (en) 2011-03-31 2012-10-04 Zentiva, K.S. Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration
US20180036382A1 (en) * 2015-02-09 2018-02-08 Entera Bio Ltd. Formulations for oral administration of active agents with controlled absorption profile
CN116850132A (zh) 2016-08-17 2023-10-10 安提拉生物有限公司 用于口服的活性剂的制剂
KR101796604B1 (ko) * 2016-08-30 2017-11-10 목포대학교 산학협력단 위장관 흡수증진제를 함유하는 부갑상선 호르몬의 경구 투여 제형

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
RU2112515C1 (ru) * 1991-12-17 1998-06-10 Проктер энд Гэмбл Фармасьютикалз, Инк. Способ лечения остеопороза
EP0679088B1 (de) * 1992-09-29 2002-07-10 Inhale Therapeutic Systems Pulmonale abgabe von aktiven fragmenten des parathormons
DK0915911T3 (da) * 1996-08-02 2004-03-08 Ca Nat Research Council Analoger til parathyreoideahormon til behandling af osteoporose
ATE383169T1 (de) * 1997-02-07 2008-01-15 Emisphere Tech Inc Komponente und zusammensetzungen zur verabreichung von wirkstoffen
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
DE69938064T2 (de) * 1998-11-25 2009-01-15 The General Hospital Corp., Boston Aminoterminal modifizierte parathyroidhormon (pth) analoge
ES2235854T3 (es) * 1999-04-05 2005-07-16 Emisphere Technologies, Inc. Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos.
US6900344B2 (en) * 2000-03-21 2005-05-31 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides via a dicarboxylate intermediate
JP5073153B2 (ja) 2001-06-01 2012-11-14 ノバルティス アーゲー 副甲状腺ホルモンおよびカルシトニンの経口投与
KR20040030120A (ko) * 2001-08-17 2004-04-08 노파르티스 아게 부갑상선 호르몬 단편의 경구 전달제로서의 5-ｃｎａｃ
US20070065505A1 (en) * 2003-07-11 2007-03-22 Shoufeng Li Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form

Also Published As

Publication number Publication date
DE60233803D1 (de) 2009-11-05
US9272040B2 (en) 2016-03-01
KR20040030120A (ko) 2004-04-08
US20060217313A1 (en) 2006-09-28
NO20040598L (no) 2004-02-10
HUP0401441A3 (en) 2012-09-28
JP2009242410A (ja) 2009-10-22
AU2002333443B2 (en) 2006-06-29
RU2004107899A (ru) 2005-05-10
US20040242478A1 (en) 2004-12-02
PT1420827E (pt) 2009-12-15
SI1420827T1 (sl) 2010-01-29
EP1420827B8 (de) 2009-12-23
CO5560586A2 (es) 2005-09-30
RU2322256C2 (ru) 2008-04-20
IL159714A (en) 2010-12-30
ZA200400242B (en) 2004-11-18
NO328069B1 (no) 2009-11-23
AU2002333443C1 (en) 2009-10-08
WO2003015822A1 (en) 2003-02-27
CN1279981C (zh) 2006-10-18
BR0211932A (pt) 2004-10-26
ECSP044961A (es) 2004-03-23
HUP0401441A2 (hu) 2004-12-28
MXPA04001418A (es) 2004-05-27
EP1420827B1 (de) 2009-09-23
US20090264367A1 (en) 2009-10-22
NZ531018A (en) 2006-03-31
JP2005501852A (ja) 2005-01-20
US20120088725A1 (en) 2012-04-12
PL210258B1 (pl) 2011-12-30
JP4959917B2 (ja) 2012-06-27
IL159714A0 (en) 2004-06-20
CA2453646C (en) 2008-09-30
CA2453646A1 (en) 2003-02-27
PL365388A1 (en) 2005-01-10
CY1109661T1 (el) 2014-08-13
CN1543357A (zh) 2004-11-03
DK1420827T3 (da) 2009-12-21
ES2333587T3 (es) 2010-02-24
EP1420827A1 (de) 2004-05-26
BRPI0211932B1 (pt) 2016-12-06

Similar Documents

Publication Publication Date Title
DE60233803D1 (de) 5-cnac zur oralen verabreichung von parathormonfragmenten
ATE500218T1 (de) Mittel zur behandlung von erkrankungen, die mit knochenschwund einhergehen, mit ep4-agonist als wirkstoff
MXPA03007837A (es) Composiciones para suministrar bisfosfonatos.
SG148037A1 (en) Fgf variants and methods for use thereof
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
IL220043A0 (en) Methods for producing ??-galactosidase a compositions
WO2002041837A3 (en) Treatment of mucositis
WO2005115441A3 (en) Compositions and methods for enhanced mucosal delivery of parathyroid hormone
IL175158A0 (en) Tocopherol-modified therapeutic drug compounds
ES2190244T3 (es) Uso de la hormona paratiroidea constituida por una secuencia de aminoacidos 1-34 de la hormona paratiroidea humana para reducir el riesco de fracturas oseas vertebrales y no vertebrales.
GT199700009AA (es) Terapia combinada para la osteoporosis
MXPA04003858A (es) Antagonistas de mch para el tratamiento de obesidad.
DK1001802T3 (da) Farmaceutisk kombinationspræparat af parathyroidhormon og en knogleresorptionsinhibitor
ATE356631T1 (de) Orale verabreichung von parathyroidhormon und calcitonin
ATE532523T1 (de) Zoledronsäure zur prävention oder verminderung von sekundärfrakturen nach hüftfraktur
PE20000644A1 (es) Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea
PL368686A1 (en) Novel aminobenzoephenones
BR0013416A (pt) Droga, uso de uma droga selecionada do grupo que consiste de pelo menos um bisfosfonato, e, método para tratamento de um osso fraturado
AU2002319223A1 (en) Medicament for treating tumours and their metastases using a binding molecule against bone-sialoprotein
IL157150A0 (en) Heterocarpine, a human ghrh-binding protein
ATE329613T1 (de) Wachstumhormone inhibitoren enthaltende pharmazeutische zubereitungen oder ihre biologisch aktive fragmente zur behandlung von uterinen myomas
MXPA05003633A (es) 2"-oxo-voruscharina y derivados de la misma.
UA34163A (uk) Спосіб стимулювання остеогенезу при хірургічних втручаннях на кістках щелепи
EP1408043A8 (de) 2" Oxo-Voruscharin und Analoge davon
UA33294A (uk) Спосіб реабілітації хворих після металоостеосинтезу внутрішньосуглобових переломів.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1420827

Country of ref document: EP